Intervention not reported
Requirement for inotropic support (scale from 0 to 28, days of catecholamine use) · adult (≥ 18 years of age) patients receiving mechanical ventilation (via either an endotracheal tube or a tracheostomy) for acute…
1 finding from 1 review
Intervention not reported
Requirement for renal replacement therapy ( · adult (≥ 18 years of age) patients receiving mechanical ventilation (via either an endotracheal tube or a tracheostomy) for acute…
It is very uncertain whether the intervention changes requirement for renal replacement therapy ( (very low certainty).
1 finding from 1 review
Intervention not reported
Quality of life · adult (≥ 18 years of age) patients receiving mechanical ventilation (via either an endotracheal tube or a tracheostomy) for acute…
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
OS · adults with Hodgkin's lymphoma
1 finding from 1 review
QoL · adults with Hodgkin's lymphoma
1 finding from 1 review
PFS · adults with Hodgkin's lymphoma
1 finding from 1 review
Response rate · adults with Hodgkin's lymphoma
1 finding from 1 review
Treatment‐related mortality · adults with Hodgkin's lymphoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events · adults with Hodgkin's lymphoma
1 finding from 1 review
SAEs · adults with Hodgkin's lymphoma
1 finding from 1 review
Time to death from any cause (here: overall mortality at 12‐month
Pembrolizumab probably leads to lower time to death from any cause (here: overall mortality at 12‐month compared with chemotherapy (moderate certainty).
1 finding from 1 review
Quality of life (Change from baseline to week 15)
Pembrolizumab may leads to higher quality of life (Change from baseline to week 15) compared with chemotherapy (low certainty).
1 finding from 1 review
Brain tumour response rates: complete response (CR) and partial response (PR) combinedNo. of participants: 847(6 RCTs)
Pembrolizumab probably leads to higher response rate (partial and complete response) compared with chemotherapy (moderate certainty).
1 finding from 1 review
Treatment‐related mortality
Pembrolizumab showed no clear difference in treatment‐related mortality compared with chemotherapy (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events
Pembrolizumab showed no clear difference in discontinuation due to adverse event compared with chemotherapy (low certainty).
1 finding from 1 review
Serious adverse events (irrespective of attribution to treatment)
Pembrolizumab may leads to lower serious adverse events (irrespective of attribution to treatment) compared with chemotherapy (low certainty).
1 finding from 1 review
Tranquilisation or asleep not asleep at 2 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes tranquillisation or asleep not asleep at 2 hours compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review
Global outcome ‐ need for benzodiazepine during 24 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcomes: need for benzodiazepine 2 compared with OTHER ANTIPSYCHOTIC: a. ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Specific behaviour ‐ threat or injury to self or others ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcome: general ‐ no improvement · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcome: general ‐ no overall improvement compared with COMBINATIONS: a. HALOPERIDOL + LEVOMEPROMAZINE (very low certainty).
1 finding from 1 review